Abstract
A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC). In untreated patients 25/38 (68%) with localized SCLC had raised blood levels of NSE (greater than 13 ng ml-1), in extensive disease 34/39 (87%) patients had raised NSE levels. In patients with non-small cell lung cancer (NSCLC) the serum levels were raised in 16/94 (17%). In extensive tumours of non-pulmonary origin NSE levels were increased in 24/116 (20%) patients. Longitudinal studies indicated a good correlation between the response to chemotherapy and fall of NSE levels. Tumour progression was accompanied by a rising NSE in 25/29 patients, with doubling times of 7-90 days. In patients with progression with a normal NSE the recurrence was a NSCLC. Cerebral metastases occurring as the only recurrence during clinical complete remission were not accompanied by a rise of NSE. Serum NSE levels provides a valuable monitor for SCLC during and after chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Cooper, E., Splinter, T., Brown, D. et al. Evaluation of a radioimminoassay for neuron specific enolase in small cell lung cancer. Br J Cancer 52, 333–338 (1985). https://doi.org/10.1038/bjc.1985.198
Issue Date:
DOI: https://doi.org/10.1038/bjc.1985.198
This article is cited by
-
Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion
Heart Failure Reviews (2013)
-
Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis
British Journal of Cancer (1999)
-
Clinical significance of the tumor markers CYFRA 21-1 and neuron-specific enolase in lung cancer
Bulletin of Experimental Biology and Medicine (1997)
-
Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer
Irish Journal of Medical Science (1995)
-
Neuron-specific enolase can be used as the sole guide to treat small-cell lung cancer patients in common clinical practice
Journal of Cancer Research and Clinical Oncology (1989)